💬In plain words
What the trial is, and whether it could suit you
Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.
For blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
I.T-888-DIGICARE：
Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:
1. Hypertension
* With or without treatment, and meeting one of the following:
* Office blood pressure: two consecutive measurements \>130/80 mmHg
* Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of the weekly measurements exceeding this threshold
2. Hyperlipidemia
* With or without treatment, and
* LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD)
3. Diabetes Mellitus
* With or without treatment, and
* HbA1c \>6.5%
4. Chronic Kidney Disease (CKD)
* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and
* Urine albumin-to-creatinine ratio (UACR) \>30 mg/g
5. Atherosclerotic Cardiovascular Disease (ASCVD):
* Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology
II. DREAM-G:
1. Hypertension
* With or without treatment, and meeting one of the following:
* Office blood pressure: two consecutive measurements \>130/80 mmHg
* Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of weekly measurements exceeding this threshold
2. Hyperlipidemia
* With or without treatment, and
* LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD)
3. Diabetes Mellitus
* With or without treatment, and
* HbA1c \>6.5%
4. Chronic Kidney Disease (CKD)
* Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and
* Measurable urinary microalbumin-to-creatinine ratio
5. Atherosclerotic Cardiovascular Disease (ASCVD):
• Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology
Participants must meet at least one of the above chronic disease conditions and:
6. Untreated Hypertension:
* Morning home blood pressure (HBP) \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg,
* Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg
7. Treated Hypertension:
* Morning home blood pressure \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg,
* Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg
* Average home blood pressure ≤130/80 mmHg (used to determine treatment strategy)
Exclusion Criteria:
I. T-888-DIGICARE
1. Symptomatic heart failure (New York Heart Association functional class II-IV)
2. End-stage renal disease requiring long-term dialysis
3. Pregnant women or those planning pregnancy
II. DREAM-G:
1. Life expectancy \<1 year
2. End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care
3. Severe liver cirrhosis
4. Malignancy under active treatment
💊
What it tests
- Interactive digital modules
- Antihypertensive Medication Management
United safety medical group(USMG)
New Taipei City, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky